Oral corticosteroid-dependent asthma: current knowledge and future needs by Pavord, I

Making the diagnosis of asthma. Measurement of airway responsiveness should be more readily available. by Pavord, I

Lessons from LAVOLTA by Pavord, I

Counterpoint: Should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? No. by Pavord, I

GLUCOLD, eosinophils and chronic obstructive pulmonary disease by Pavord, I

Chronic cough: a rational approach to investigation and management. by Pavord, I

Asthma phenotypes. by Pavord, I

Physiology and pathophysiology of cough by Pavord, I

Eosinophilic phenotypes of airway disease. by Pavord, I

Assessment of inflammation in COPD: Observed cell profiles and the effects of treatment by Pavord, I

Non-eosinophilic asthma and the innate immune response. by Pavord, I

Monitoring of exhaled nitric oxide in primary care. by Pavord, I

Rebuttal From Dr Pavord by Pavord, I

Biologics and chronic obstructive pulmonary diseases by Pavord, I

Asthma control, airway responsiveness and airway inflammation. by Pavord, I

Cough and asthma. by Pavord, I

Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma (Respir Med 1999; 93: 245-251) by Pavord, I

Sputum induction to assess airway inflammation: is it an inflammatory stimulus? by Pavord, I

Mepolizumab, quality of life, and severe eosinophilic asthma. by Pavord, I

Complex airway disease: an approach to assessment and management. by Pavord, I